MeiraGTx (MGTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

MeiraGTx (MGTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.79

0.02 (0.35%)

At close: Jan 15, 2025, 12:09 PM

undefined% (undefined)

Bid	5.78
Market Cap	452.51M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.2
PE Ratio (ttm)	-4.82
Forward PE	n/a
Analyst	Buy

Ask	5.8
Volume	90,274
Avg. Volume (20D)	318,222
Open	6.03
Previous Close	5.77
Day's Range	5.75 - 6.08
52-Week Range	3.85 - 7.37
Beta	undefined

About MGTX

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical develop...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 8, 2018

Employees 387

Stock Exchange NASDAQ

Ticker Symbol MGTX

Website https://www.meiragtx.com

Analyst Forecast

According to 2 analyst ratings, the average rating for MGTX stock is "Buy." The 12-month stock price forecast is $23.5, which is an increase of 305.87% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

MeiraGTx is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $1.50M, reflecting a -26.47% YoY shrinking and earnings per share of -0.48, making a -214.29% decrease YoY.

Why Price Moved

3 months ago · Source

+14.87%

MeiraGTx shares are trading higher after safety an... Unlock content with Pro Subscription

News

1 month ago · seekingalpha.com

MeiraGTx Holdings: Behind The Recent Rally

MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeli...

2 months ago · zacks.com

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.74 per share a year ago.

3 months ago · zacks.com

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.

3 months ago · zacks.com

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago · seekingalpha.com

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase ...